[ Pobierz całość w formacie PDF ]
.Eur J Pharmacol 461: 27 3427 Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, MaruaniJ, Neliat G, Caput D, Le Fur G (1994) SR141716A, a potent and selective antagonist of the braincannabinoid receptor.FEBS Lett 350: 240 24428 Williams CM, Kirkham TC (2002) Reversal of [Delta]9-THC hyperphagia by SR141716 andnaloxone but not dexfenfluramine.Pharmacol Biochem Behav 71: 333 34029 Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, Le Fur G (1997) Selectiveinhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1)receptors.Psychopharmacology 132: 104 10630 Simiand J, Keane M, Keane PE, Soubrie P (1998) SR141716, a CB1 cannabinoid receptor antag-onist, selectively reduces sweet food intake in marmoset.Behavi Pharmacol 9: 179 18131 Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL (1998) Appetite suppression andweight loss after the cannabinoid antagonist SR141716.Life Sci 63: L113 L11732 Freedland CS, Sharpe AL, Samson HH, Porrino LJ (2001) Effects of SR141716A on ethanol andsucrose self-administration.Alcohol Clin Exp Res 25: 277 28233 Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie P (2003)Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice.Am JPhysiol Regul Integr Comp Physiol 284: R345 R35334 Hildebrandt AL, Kelly-Sullivan DM, Black SC (2003) Antiobesity effects of chronic cannabinoidCB1 receptor antagonist treatment in diet-induced obese mice.Eur J Pharmacol 462: 125 13235 Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD,Sugiura T, Kunos G (2001) Leptin-regulated endocannabinoids are involved in maintaining foodintake.Nature 410: 822 82536 Armone M, Millet L, Maffrand JP, Soubrié P (2004) Rimonabant reduces weight gain in obesezucker rats by regulating hyperphagia and activating fatty acid oxidation.In: Abstracts of the 13thEuropean Congress on Obesity (ECO), Prague, Czech Republic, 26 29 May 2004.Int J ObesRelat Metab Disord 28(Suppl.1): 7737 Rinaldi-Carmona M, Barth F, Congy C, Martinez S, Oustric D, Pério A, Poncelet M, Maruani J,Arnone M, Finance O et al.(2004) SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)- Cannabinoids in appetite and obesity 2294-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist ofthe CB1 cannabinoid receptor: biochemical and pharmacological characterizaztion.J PharmacolExp Ther 310: 905 91438 Fong MT, Goulet M, Hagman W, Plummer C, Finke P, Mills S, Shah S, Truong Q., Shen C, Lao,J, Van der Ploeg L (2003) Biological and pharmacological activity of new CB1R inverse agonist,2003 Symposium on the Cannabinoids p 1, International Cannabinoid Research Society,Burlington, Vermont39 Smith R.A, O Connor SJ, Wirtz SN, Wong WC, Choi S, Kluender HC, Su N, Wang G, Achebe F,Ying S (2003) Imidazole-4-carboxamide derivatives, preparation and use thereof for the treatmentof obesity.International Patent Application WO 03/04010740 Le Fur G, Arnone M, Rinaldi-Carmona M, Barth F, Heshmati H (2001) SR141716, a selectiveantagonist of CB1 receptors and obesity, 2001 Symposium on the Cannabinoids p.101International Cannabinoid Research Society, Burlington, Vermont41 Jensen M, Abu-Lebdeh H, Geohas J, Brazg R, Block M, Noveck R, Free R (2004) The selectiveCB1 receptor antagonist rimonabant reduces body weight and waist circumference in obese sub-jects.Int J Obesity 28 (Suppl.1): Abst T5:O2-00142 Dale L, Anthenelli R, Després JP, Golay A, Sjostrom L (2004) Effects of rimonabant in the reduc-tion of major cardiovascular risk factors: results from the STRATUS-US trial (Smoking cessationin smokers motivated to quit) and the RIO-LIPIDS trial (Weight reduction and metabolic effectsin overweight/obese patients with dyslipidemia).American College of Cardiology AnnualScientific Sessions, Presentation 409-1, March 7 10, 2004, New Orleans43 Houri M, Pratley RE (2005) Rimonabant: a novel treatment for obesity and the metabolic syn-drome.Curr Diab Rep 5: 43 4444 Van Gaal L (2004) RIO-EUROPE: a randomized double-blind study of weight reducing effect andsafety of rimonabant in obese patients with or without comorbidities, European Society ofCardiology Congress, Presentation 106, August 28 September 1, 2004, Munich45 Schwartz MW, Woods SC, Porte D, Jr, Seeley RJ, Baskin DG (2000) Central nervous system con-trol of food intake.Nature 404: 661 67146 Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M,Bouaboula M, Calandra, Le Fur G (1998) SR 144528, the first potent and selective antagonist ofthe CB2 cannabinoid receptor.The.J Pharmacol Exp Ther 284: 644 65047 Poncelet M, Maruani J, Calassi R, Soubrie P (2003) Overeating, alcohol and sucrose consumptiondecrease in CB1 receptor deleted mice.Neurosci Lett 343: 216 21848 Hilairet S, Bouaboula M, Carriere D, Le Fur G, Casellas P (2003) Hypersensitization of theOrexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antag-onist, SR141716.The.J Biol Chem 278: 23731 2373749 Verty AN, McFarlane JR, McGregor IS, Mallet PE (2004) Evidence for an interaction betweenCB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake.Endocrinology145: 3224 323150 Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P (2002) SR141716, a central cannabinoid(CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine inrats.Behavi Pharmacol 13: 451 46351 Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR (2003) The cannabinoid CB1antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carbox-amide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous rein-forcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats.The [ Pobierz caÅ‚ość w formacie PDF ]

  • zanotowane.pl
  • doc.pisz.pl
  • pdf.pisz.pl
  • blondiii.htw.pl
  •